MCM
CBAY

Moore Capital Management’s Cymabay Therapeutics CBAY Stock Holding History

Moore Capital Management’s Portfolio CBAY Stock Details CBAY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q3 		– Sell
-25,000
Closed -$179K – 396
2019
Q2 		$179K Hold
25,000
– – ﹤0.01% 300
2019
Q1 		$332K Buy
+25,000
New +$266K 0.01% 260
2018
Q2 		– Sell
-50,000
Closed -$650K – 338
2018
Q1 		$650K Hold
50,000
– – 0.01% 209
2017
Q4 		$460K Hold
50,000
– – 0.01% 235
2017
Q3 		$403K Buy
+50,000
New +$338K 0.01% 215

Other funds holding CBAY

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
EAM
Eagle Asset Management St Petersburg, Florida $19.6B AUM 41.58% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
CTA
Carillon Tower Advisers St. Petersburg, Florida $16.4B AUM 64.75% 1-Year Est. Return

Moore Capital Management's CBAY Position: Q3 2019 in Review

Moore Capital Management sold out of Cymabay Therapeutics (CBAY) in Q3 2019, closing a stake of 25,000 shares — an estimated $179K sold.

Moore Capital Management first reported a position in CBAY in Q3 2017 and held it in 5 quarters. The position peaked at $650K in Q1 2018. 137 funds tracked by Wall St. Rank hold CBAY as of Q3 2019.

  • Moore Capital Management reported no remaining Cymabay Therapeutics position as of Q3 2019 after selling out during the quarter.
  • Moore Capital Management sold 25,000 Cymabay Therapeutics shares in Q3 2019, an estimated $179K.
  • Moore Capital Management first reported a position in Cymabay Therapeutics in Q3 2017 and held it in 5 quarters.
  • Moore Capital Management's Cymabay Therapeutics position peaked at $650K in Q1 2018.
  • 137 funds tracked by Wall St. Rank held Cymabay Therapeutics as of Q3 2019.

Based on Moore Capital Management's 13F filing for Q3 2019, filed 14 Nov 2019.